Specialty deficient and inhibitor plasmas from HYPHEN BioMed and 5-Diagnostics for research and assay validation applications.

Factor XIII (FXIII/fibrin-stabilizing factor) deficient plasma supports BIOPHEN™ FXIII isopeptidase assay substrate requirements and FXIII research.

vWF deficient plasma provides the vWF-free matrix required for vWF activity and antigen assay development.

FVIII inhibitor plasmas at mild (approx 1-5 BU), moderate, and severe (>5 BU) levels validate Bethesda and Nijmegen-modified Bethesda assay performance at clinically relevant inhibitor concentrations.

FIX inhibitor plasma (mild) validates FIX Bethesda assay performance.

NAPTT FIXa positive controls (5-Diagnostics, approx 10 mIU/mL and 20 mIU/mL) are specialized controls for the Neonatal APTT (NAPTT) assay used in FIX concentrate safety testing.

Page(s): < > 1
 
Reference Product Name Price
RUO
ADP200K
 Factor XIII Deficient Plasma (6 × 1 mL) $440.00
RUO
ADP100K
 Protein C Deficient Plasma (6 × 1 mL) $440.00
RUO
ADP110K
 Protein S Deficient Plasma (6 × 1 mL) Discontinued
RUO
ADP150K
 vWF Deficient Plasma (6 × 1 mL) — Also FVIII Deficient $440.00